Podcasts about cteph

Canadian resident, Stephen Gariepy, was diagnosed with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in 2018. After initially being active in senior hockey, his condition worsened, leading to difficulty breathing and performing daily tasks. Gariepy continues to live with this rare and terminal disease, adapting to the limitations it imposes on his daily life. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada 

It's time to dust off the cobwebs and get those cogs turning in your noggin 'cause Ready Steady Learn is back for 2025 thanks to Waipapa Taumata Rau - The University of Auckland. Jonny is joined by Behdad Ebrahimi of the Auckland Bioengineering Institute to chat about his work with people with a rare, and also serious, lung condition. Chronic thromboembolic pulmonary hypertension, or CTEPH for short, is a debilitating condition even post-surgery. Ebrahimi's work involves building computer models of lungs tailor-made to patients' own that can predict how blood flow and pressure will change following surgical intervention. Whakarongo mai nei! 

Maureen Harper, a CTEPH patient from Canada, shares her journey with this rare condition. She initially thought she had an infection in her leg, but further tests revealed enlarged pulmonary arteries and multiple blood clots in her lungs. After being diagnosed with pulmonary hypertension, she underwent a complex surgery in Toronto to attempt to remove the clots. Maureen continues to work full-time as a pharmacy technician, remains active with her family and Girl Guide unit, and maintains a positive outlook, choosing to focus on the positives rather than dwell on the negatives. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @phacanada 

Tina Proulx was diagnosed with pulmonary hypertension at the age of 19. She experienced difficulty breathing and chest pain, leading to a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), a condition caused by blood clots in the lungs. Tina eventually underwent transplant and celebrated eight years post-transplant, surpassing the average lifespan post-transplant. Tina emphasizes the importance of advocating for oneself in the healthcare system and encourages others to trust their instincts and fight for their needs. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @PHACANADA

Marilyn Hanft, a CTEPH patient, shares her experience with the condition. In 2011, she initially mistook her symptoms for asthma but later discovered she had clots in her lungs. Despite her health challenges, she remains determined to live life to the fullest. Hanft discusses her love for sailing and her current plan for writing a book about her sailing experiences.  Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com

Please visit answersincme.com/CGH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses evidence and guidance on using multimodal approaches for managing patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Upon completion of this activity, participants should be better able to: Identify the continued needs with the currently available therapies for inoperable CTEPH; Review the clinical evidence for multimodal approaches in inoperable CTEPH in the context of currently available therapies; and Outline clinical factors that may facilitate optimal therapeutic selection for patients with inoperable CTEPH.

Guest host Dr. Andrew Chesley summarizes a RadioGraphics article about the alternative therapeutic option of Balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Balloon Pulmonary Angioplasty in the Management of Chronic Thromboembolic Pulmonary Hypertension. Higuchi et al. RadioGraphics 2022; 42:1881–1896.

Harm Bogaard, MD, Ph.D., FAHA is a pulmonologist at the Amsterdam UMC. In this episode, he discusses the use of magnetic resonance imaging (MRI) in monitoring pulmonary hypertension patients. Dr. Bogaard explains that MRI is a valuable tool for assessing the function and structure of the right heart, which is crucial in determining the prognosis and long-term outcomes of patients with pulmonary hypertension. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD 

On this episode of JHLT: The Podcast, the JHLT Digital Media Editors explore two studies from the February issue of The Journal of Heart and Lung Transplantation. Digital Media Editor Van-Khue Ton, MD, a transplant cardiologist at Massachusetts General Hospital, hosts this episode.   First, Dr. Ton and Digital Media Editor Erika Lease, MD interview their first guest, David Jenkins, FRCS(Cth), of the Royal Papworth Hospital in Cambridge, UK. Dr. Jenkins was senior author on the study “Perioperative extracorporeal membrane oxygenation support for pulmonary endarterectomy: A 17-year experience from the UK national cohort.” In the conversation, Dr. Jenkins shares the major determinants of mortality in this patient population, differences between survivors and non-survivors, and the CTEPH classification systems involved.   Next, Dr. Ton is joined by Digital Media Editor Marty Tam, MD, to interview their next guest, Kevin Chen, a 4th year general surgery resident at Cedars-Sinai Medical Center. Dr. Chen was a first author on the study “Heart transplantation in patients from socioeconomically distressed communities.” Drs. Ton and Tam lead a lively discussion about this important paper, including the methodology behind the indices used to categorize patients, and the million-dollar question: why did patients from distressed communities fare more poorly?   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode, Drs. Patricia George and Harrison "Hap" Farber from Team PHenomenal Hope discuss takeaways and learning from PHenomenal Hope 2023. This symposium offered a combination of oral presentations, expert panel discussions, and poster sessions in an environment that encourages collaboration and a deeper exploration of patient-centered research.  They also discuss Team PH's 2024 Research Award program, looking for topics that will help expand access to care and improve clinical status by looking specifically for projects in the topic areas outlined at the PHenomenal Hope 2023 research meeting.  Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD 

Harm Bogaard, MD, Ph.D., FAHA is a pulmonologist at the Amsterdam UMC. In this episode, he discusses the role of genetic testing in the treatment of patients with pulmonary hypertension at its role in clinical research. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD 

CME credits: 4.75 Valid until: 30-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-2-and-panel-cteph-and-ph/16520/ The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

CME credits: 4.75 Valid until: 30-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/panel-discussion-simulated-cteph-case-conference/16510/ The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

CME credits: 4.75 Valid until: 30-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-thromboendarterectomy-for-cteph/16509/ The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

CME credits: 4.75 Valid until: 30-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/cteph-cted-current-epidemiology-and-trends/16507/ The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

CME credits: 4.75 Valid until: 30-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-study-a-62-year-old-male-with-cteph/16506/ The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies LAA occlusion Chronic thromboembolic pulmonary hypertension Mythbusters: Do cholesterol lowering drugs provoke dementia? Host: Perry Elliott Guests: Carlos Aguiar, Stephan Rosenkranz, Jacqueline Saw Want to watch that episode? Go to: https://esc365.escardio.org/event/1140   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.    Declarations of interests Stephan Achenbach and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.  Stephan Rosenkranz has declared to have potential conflicts of interest to report: speaker fees and consultation for Bayer, MSD, Boehringer-Ingelheim and Inari. Jacqueline Saw has declared to have potential conflicts of interest to report: proctor and consultancy fees from Abbott and Boston Scientific. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

It's pulmonary hypertension month on JHLT: The Podcast! The JHLT Digital Media Editors explore two PVD-related manuscripts from the November issue of The Journal of Heart and Lung Transplantation. Digital Media Editor Marty Tam, MD, assistant professor in the division of cardiovascular medicine at the University of Michigan, hosts this episode.   First, hear from first author Zvonimir Rako, MD, on his team's study “Clinical and functional relevance of right ventricular contraction patterns in pulmonary hypertension.”   The right ventricle (RV) has a complex contraction pattern. For patients with pulmonary hypertension (PH), right ventricular to pulmonary artery (RV-PA) coupling is important when considering how the RV responds to increases in afterload. Uncoupling occurs with progressive disease and the degree of uncoupling can be derived from pressure–volume loop analysis as the ratio between end-systolic and arterial elastance (Ees/Ea).   In this exploratory analysis of the prospective EXERTION study, the authors determined the relationship between RV contraction patterns and RV-PA coupling in patients with PH. They also correlated RV contraction patterns to hemodynamic risk profiles. For details on what the study found about how PH programs can use the results in their practice, listen to the discussion in the episode.   Next, the editors explored the study “Impact of sex on outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.” The podcast hosted first author Justin C.Y. Chan, MD, MPhil and senior author Marc de Perrot,  MD, MSc, FRCSC.   The impact of sex on long-term outcomes after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH) has remained unclear. The authors of this study sought to evaluate the early and long-term outcomes after pulmonary endarterectomy to see if sex had an impact on the risk of residual pulmonary hypertension and need for targeted PH medical therapy.    For details on what this retrospective single-center study found, including the mechanics of sex differences and the potential changes to clinical approach, check out the episode.   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation.  Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

CME credits: 4.25 Valid until: 31-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/focus-on-ctephcted/16323/ This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

CME credits: 4.25 Valid until: 31-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-study-cteph/16321/ This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host Dr. Praveen Ranganath speaks with Drs. Seth Kligerman, Albert Hsia, and  Francisco Contijoch about their article on Mapping the Spatial Extent of Hypoperfusion in Chronic Thromboembolic Pulmonary Hypertension Using Multienergy CT.  Mapping the Spatial Extent of Hypoperfusion in Chronic Thromboembolic Pulmonary Hypertension Using Multienergy CT. Bird et al Radiology: Cardiothoracic Imaging 2023; 5(4):e220221

CardioNerds cofounders Dr. Amit Goyal and Dr. Daniel Ambinder join Dr. Isabel Balachandran, Dr. Diego Celli from the Texas Heart Institute. They discuss the nuances of risk stratification management of intermediate risk pulmonary embolism. The ECPR for this episode was provided by Dr. Alam Mahboob (Associate Professor of Medicine at Baylor College of Medicine and the Department of Medicine and Associate Program Director for the Cardiovascular Disease Fellowship Program at Baylor). Audio editing by CardioNerds Academy Intern, Dr. Chelsea Amo Tweneboah. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - Caring for the Middle Child of Pulmonary Embolism – Texas Heart Institute Pearls - Caring for the Middle Child of Pulmonary Embolism – Texas Heart Institute Submassive pulmonary embolism is defined as an intermediate risk group of acute pulmonary embolism, which presents with signs of RV dysfunction and myocardial injury without hemodynamic instability. The AHA, ACCP, and ESC have variable definitions of submassive PE. Non-invasive tools such as EKG, TTE, and CT are critical to defining RV dysfunction. The Pulmonary Embolism Severity Index (PESI) score is a validated tool to help risk stratify patients with PE. Advanced therapies for submassive PE include systemic thrombolysis, catheter-based intervention, surgical embolectomy, and mechanical circulatory support. The decision between these therapies is based on individual patient risk profiles, local expertise, and the risk of major bleeding. There is a spectrum of long-term complications after an acute PE, ranging from post PE syndrome to CTEPH (chronic thromboembolic pulmonary hypertension) caused by a maladaptive vascular remodeling from residual thrombus or arteriopathy. Thrombolytic therapies are still controversial in reducing the risk of post PE complications. PERT is a multidisciplinary group of clinicians who can rapidly assess and triage patients with acute PE, coordinate access to medical and advanced therapies, and provide the necessary follow up care. Show Notes - Caring for the Middle Child of Pulmonary Embolism – Texas Heart Institute How do you define “submassive” pulmonary embolism? Venous thromboembolism, which includes deep vein thrombosis and acute pulmonary emboli (PE) are the third most common cardiovascular disorder in the United States with approximately 900,000 cases occurring each year (1). The morbidity and mortality associated with pulmonary emboli are also great, with approximately 33% of PE cases being fatal (1).Until recently, PE was previously classified into massive or non-massive. Massive PE was defined as those with cardiogenic shock. A newer group, “submassive PE”, was defined as an “intermediate” risk group. According to the American Heart Association (AHA) Scientific Statement on the management of massive and submassive PE, patients in this group presented with signs of RV dysfunction and myocardial necrosis without hemodynamic instability (2). Intermediate-risk PE covers a broad range of risk and management decisions remain challenging. Intermediate-risk PE convers increased risk for mortality and complications compared with low-risk PE.  How do you risk-stratify intermediate-risk pulmonary emboli? The AHA, American College of Chest Physicians (ACCP), and European Society of Cardiology (ESC) have variable definitions of submassive PE and which biomarkers should be used (1,3). The contents are summarized as below (Table 1) Each major guideline highlights the importance of the evaluation of RV dysfunction (RVD) and elevated biomarkers. To summarize,

In this episode, respiratory registrar and MEMcast host Dr Rachel Saville explains an approach to PE followup. Find out how to assess a patient's risk for future PEs, and why there is a shift towards recommending lifelong anticoagulation in unprovoked PE. Finally, you will learn about one of the complications of PE, CTEPH. Happy listening! 

Drs. Meghan Cirulis and Khushboo Goel discuss chronic thromboembolic pulmonary hypertension (CTEPH) with international expert, Dr. Kim Kerr. 

In this episode, PAH and CTEPH patient, Kristine Setser details her PAH diagnosis and her rare, life-saving thromboendarterectomy surgery which she believed to be was her only shot at life. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate  #phaware Share your story: info@phaware.com

This month's JHLT: The Podcast is hosted by Digital Media Editor David Schibilsky, MD, who leads a discussion of two studies from the March issue of The Journal of Heart and Lung Transplantation—and the first authors who presented them.   First, the editors explore a study entitled “Angiopoietin 2 and hsCRP are associated with pulmonary hemodynamics and long-term mortality respectively in CTEPH—Results from a prospective discovery and validation biomarker study,” which comes from Hadinnapola and colleagues at the Papworth group in Cambridge, UK.   The editors welcome Charaka Hadinnapola, MA, MB, BChir, first author on the CTEPH study, to share the rationale in performing the research, its main findings, the changing understanding of the pathobiology of pulmonary arterial hypertension, and how Ang2 and hsCRP fit into the bigger cytokine picture in CTEPD and CTEPH patients.   Next, the editors welcome author J.K. Peel, MD, MSc, from the University of Toronto to discuss the paper her first authored, “Determining the impact of ex-vivo lung perfusion on hospital costs for lung transplantation: a retrospective cohort study.”   This retrospective, before-after, propensity-score weighted cohort study explores how EVLP affects hospital costs and the associated transplant procedures, intending to evaluate whether the benefits of EVLP offset its additional cost. Dr. Peel shares what changes occurred at his center during the study period, how the results compare to other published evidence on EVLP costs, and whether the results are transferable to smaller centers.   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation.  Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.    

Dr. Zachary Steinberg, MD, is a board-certified Interventional Cardiologist and Adult Congenital Heart Disease specialist with the UW Medicine's Heart Institute. Dr. Steinberg specializes in the care of adults born with heart defects and performs transcatheter intervention on this complex patient population.  He has a wide array of interventional expertise including complex coronary artery revascularization, transcatheter valve implantation, septal defect closure, and balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension (CTEPH).00:55 - Dr. Specialization13:00 - "A Profession of Lifelong Learning"15:10 - Intervention Cardiology First19:45 - A Day in the Life - Chronic thromboembolic pulmonary hypertension28.25 - Learning Chronic Pulmonary Angioplasty36:45 - Approaching Orphan Diseases37:30 - Our Interventional Team39:50 - Repairing Congenital Defectsuwheart@uw.edu

In this episode, host Dr. Aaron Fritts interviews interventional cardiologist Dr. Rohit Amin about his private practice PE response team, including his treatment algorithm, follow-up protocol, and how he believes AI can contribute to PE care. --- CHECK OUT OUR SPONSOR RapidAI http://rapidai.com/?utm_campaign=Evergreen&utm_source=Online&utm_medium=podcast&utm_term=Backtable&utm_content=Sponsor --- SHOW NOTES Dr. Amin trained at Ochsner Clinic in New Orleans, and now works in private practice in Pensacola, Florida. He and a partner decided to start a PE response team (PERT) to better serve patients in the area and expand their practice. It took a lot of groundwork. They had to pitch it to administration and raise awareness, which they did by hosting CME such as grand rounds. They struggled to get a pulmonologist on board in 2013 when there was less clinical data and guidelines. Next, we discuss how the PERT algorithm functions in his private practice. An ER doctor or hospitalist evaluates the patient first. If the CT shows proximal thrombus, the PERT is notified. If it is a massive PE or submassive with clinical severity, he does thrombectomy promptly. If there is no elevated troponin and normal hemodynamics, the patient gets admitted and evaluated with a stat echo and venous doppler. Dr. Amin's practice prefers an echo with PE protocol to risk stratify RV dysfunction - i.e. RV size, tricuspid annular plane systolic excursion (TAPSE). He also evaluates pulmonary artery (PA) pressure, PA saturation, and cardiac index which are important clinical factors that determine the optimal route of intervention. For patients with submassive PE who get admitted overnight, he gives all patients a heparinoid, preferably lovenox over heparin. He sees the patient in the morning and if the clot is submassive or proximal, he does a thrombectomy that day. Lastly, we cover the importance of treating PE and how Dr. Amin approaches longitudinal follow up. Dr. Amin refers to the ICOPER trial that showed that the 30 day mortality for submassive PE is 15%, higher than that of NSTEMIs. If a PE is left untreated or if treatment is significantly delayed, a patient can develop post-PE syndrome or chronic thromboembolic pulmonary hypertension (CTEPH), which significantly worsen morbidity and mortality. Dr. Amin treats his PE / DVT patients with one week of lovenox before transitioning to a direct oral anticoagulant (DOAC). He sees them in the office in one month and gets an echo at 3 months. He then sees patients semi-annually or annually for 3-5 years. --- RESOURCES BackTable Episode 196: https://www.backtable.com/shows/vi/podcasts/196/building-a-pe-response-team PERT Consortium: https://pertconsortium.org ICOPER Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07534-5/fulltext

CTEPH patient, Karri Reynolds spent years bouncing from specialist to specialist due to her failing health. In this episode, she details how self-advocating led and a desperate facebook post led to her being diagnosed at age 40 (by a pediatric cardiologist)! Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials Share your story: info@phaware.com

Join us in our 34th clinical episode as we discuss the basics and the pathophysiology of Pulmonary Embolism. We discuss Massive, Submassive, Sub-Acute Massive, and CTEPH, as well as a deeper dive into the patho behind increased right ventricular pressure, and decreased oxygenation.  Join us in the next episode where we will dive in to the assessment and diagnostic principles of PE.   

Chronic Thromboembolic Pulmonary Hypertension Guest: Vidhu Anand, MBBS, FACC, FASE (@vidhu_anand) Host: Malcolm R. Bell, M.D. Patients with Chronic Thromboembolic Pulmonary Hypertension have a life expectancy of one to three years if left untreated. CTPH is usually caused by blood clots that are prolonged in the body for a certain period. In addition, the blood tends to back up into the lungs, which increases the patient's blood pressure. Some risk factors that can lead to CTPH are obesity, smoking, and cancer. Joining us today to discuss Chronic Thromboembolic Pulmonary Hypertension is Vidhu Anand, MBBS, FACC, FASE, assistant professor of medicine at Mayo Clinic in Rochester, Minnesota. Specific topics discussed: What is chronic thromboembolic pulmonary hypertension? How is it diagnosed? What are different treatment options for management of CTEPH? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.    

In this episode, CTEPH patient, Carol Templeton details her complex surgery, called pulmonary thromboendarterectomy (PTE), which involves the removal of chronic clots from the lung vessel and the impact it had on her as the adoptive mom to her 18 month old daughter. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials Share your story: info@phaware.com

PH, PAH, CTEPH...an intensivist's favorite type of alphabet soup!

CME credits: 1.00 Valid until: 30-06-2023 Claim your CME credit at https://reachmd.com/programs/cme/vq-scans-and-computed-tomographic-approaches-to-ph-diagnosis-finding-cteph/14188/ TBD

Do you know how and when to make the diagnosis of CTEPH? Listen in as our experts discuss the latest tools for diagnosis and management. Credit available for this activity expires: 5/23/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/974245?src=mkm_podcast_addon_974245

CME credits: 2.00 Valid until: 15-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/a-case-of-cteph-what-to-do/14032/ tbd

CME credits: 2.00 Valid until: 15-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/a-case-of-cteph-what-to-do/14032/ tbd

Happy Tuesday friends! Welcome back to another episode of That's So Chronic. Today I'm down in sunny Dunedin to interview Olivia Leonard, who is living with a diagnosis of Chronic Thromboebolic Pulmonary Hypertension or CTEPH for short. In this episode Olivia shares with us the lead up of events that resulted in the doctors finding a blood clot in her lungs, how she manages studying as well as her symptoms, what being diagnosed with CTEPH has taught her about life, and the dilemma of being at risk of developing severe illness with the cov, while being medically exempt from wearing a mask. Just a note, this episode was recorded in October 2021. As always, I love hearing from you! So don't be afraid to reach out over on instagram or tiktok, I'm @thatssochronic. All additional information is below… And I'll see you next week! @thatssochronic | @jessssbrien | #thatssochronic Free monthly newsletter: thatssochronic.substack.com Application form to share your story: https://forms.gle/csebLkwfwAjiLApK9 Ideas for That's So episodes: https://forms.gle/4RZbCiHARjV5gmcWA Disclaimer: Here at That's So Chronic we are sharing personal stories and are not advocating any type of treatment, therapy, procedure or intervention. Everyone is unique so please seek professional medical advice before making any decisions for yourself or for others. Hosted on Acast. See acast.com/privacy for more information.

Cardionerds, Tommy and Dinu, present a case to Dr. Vaidya, Lindsey, and Dan. Dr. Anjali Vaidya Dr. Vaidya is a heart failure and transplant cardiologist at the Lewis Katz School ofMedicine at Temple University, where she serves as the co-director of the Pulmonary Hypertension, right heart failure, and CTEPH program, as well as a PD… Read More »Episode 225: The Consult Question #6 Featuring CardioNerds – Shortness of Breath

This episode of Food, Freedom and Fertility is in honor of Valentine's Day and also because February is PCOS Awareness for heart health risk.  The guest this week is Dr. Jennifer Haden Haythe. Dr. Haythe specializes in Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology.  Dr. Haythe graduated from Harvard University in 1995. She completed her medical school and residency training at Columbia University College of Physicians and Surgeons in 2003. After finishing a congestive-heart failure-cardiac transplant fellowship at Columbia in 2005 she went on to complete her fellowship training in cardiovascular diseases there in 2009. She is currently an Assistant Professor of Medicine in the Division of Cardiology, Center for Advanced Cardiac Care at Columbia and Co-Director of the Women's Center for Cardiovascular Health. Dr. Haythe specializes in pulmonary hypertension, heart failure, and cardiac transplant. She has a special interest in chronic thromboembolic pulmonary hypertension (CTEPH) and the care of pregnant women with cardiovascular diseases.

Derek Henderson is a #CTEPH patient from Toronto, Canada. In this episode Derek discusses is road to diagnosis with a rare form of pulmonary hypertension, the mental challenge of PTE surgery and the misconceptions of Canada's socialized medicine program. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials

Interventional Cardiologist Behnam Tehrani and Interventional Radiologist Reha Butros from Inova Health System tell us about their team approach to endovascular treatment of chronic thromboembolic pulmonary hypertension (CTEPH) with Balloon Pulmonary Angioplasty (BPA). --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/TCTEY3 --- SHOW NOTES In this episode, interventional radiologist Dr. Reha Butros, interventional cardiologist Dr. Behnam Tehrani, and our host Dr. Michael Barraza discuss chronic thromboembolic pulmonary hypertension (CTEPH) and medical, endovascular, and surgical treatment options for CTEPH. CTEPH affects patients of all different ages and medical histories. While it has been associated with prior pulmonary embolism, it can also arise in patients due to blood clotting disorders and infected pacemakers. Both Dr. Butros and Dr. Tehrani stress the importance of collaborating with pulmonary hypertension experts to identify CTEPH patients before right sided heart failure occurs. CTEPH is diagnosed with dual energy CT, which shows perfusion, and right heart catheterization, which measures blood pressure. The three treatment options discussed are medical management, balloon pulmonary angioplasty (BPA), and pulmonary thromboendarterectomy (PTE). Medical management is discussed as an initial treatment for CTEPH, while PTE can be appropriate for good surgical candidates. Finally, Dr. Butros and Dr. Tehrani present BPA as an appropriate treatment for patients of all ages. BPA over multiple sessions and increasing balloon size has been shown to be effective at promoting pulmonary artery remodeling and dilation. The doctors share their own experiences with learning BPA technique, noting that it has a learning curve, but it is ultimately rewarding when patients' quality of life is improved.

CTEPH, the rare yet increasing complication of pulmonary embolism. We discuss the surgical management of CTEPH, when to refer, evaluation timeline, and key points which you should not miss. Dr. Jon Haft, MD, is an Associate Professor of Cardiothoracic Surgery at University of Michigan Medical Center.

Θρομβώσεις από COVID-19 & εμβόλια, HoT-PE trial, επεμβατικές θεραπείες σε PE, διάρκεια θεραπείας, post-PΕ syndrome & CTEPH, καρκίνος & PE

Cardiac - CTEPH (Nicholas Oh & Michael Tong) by TSRA

All pulmonary hypertension is not the same, and it’s important to differentiate among the five different subtypes to ensure effective management. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with pulmonary hypertension expert Martha Kingman, FNP-C, DNP, about the classification system for pulmonary hypertension, how to distinguish the five subtypes clinically, and best practices in management. This episode is available for CE/CME credit.

A number of specific therapies are now available for pulmonary arterial hypertension (PAH), and the outlook for patients with PAH has never been better. But first PAH must be differentiated from the other forms of pulmonary hypertension. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with pulmonary hypertension expert Martha Kingman, FNP-C, DNP, about establishing the diagnosis of PAH, determining the subcategory of PAH, today’s approach to management, and the important role of primary care NPs and PAs in long-term follow-up. This activity is available for CE/CME credit.

Join Drs. Alain Bouchard, David McGiffin, and Jason Guichard as they discuss CTEPH — also known as chronic thromboembolic pulmonary hypertension.About the Team Dr. Alain Bouchard is a clinical cardiologist at Cardiology Specialists of Birmingham, AL. He is a native of Quebec, Canada and trained in Internal Medicine at McGill University in Montreal. He continued as a Research Fellow at the Montreal Heart Institute. He did a clinical cardiology fellowship at the University of California in San Francisco. He joined the faculty at the University of Alabama Birmingham from 1986 to 1990. He worked at CardiologyPC and Baptist Medical Center at Princeton from 1990-2019. He is now part of the Cardiology Specialists of Birmingham at St. Vincent’s Health System, Ascension. Dr. Mustafa Ahmed is a Structural Heart Specialist, Interventional Cardiologist and Scientist, and is the director of the Structural Heart Disease Program at UAB. He is a leading performer of minimally invasive heart procedures, including the Mitraclip procedure. He is credited with several first of their kind procedures and internationally recognized in areas including valvular and surgical heart disease and POTS. He was born in Nottingham, England, and went to medical school at the Victoria University of Manchester. He took postgraduate positions at the Manchester Royal Infirmary, then the Queens Medical Center. Dr Ahmed moved to Birmingham, AL, where he was the first person selected for the Physician Scientist Training Program with specialization in cardiology and interventional cardiology.Medical DisclaimerThe contents of the MyHeart.net podcast, including as textual content, graphical content, images, and any other content contained in the Podcast (“Content”) are purely for informational purposes. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on the Podcast! If you think you may have a medical emergency, call your doctor or 911 immediately. MyHeart.net does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Podcast. Reliance on any information provided by MyHeart.net, MyHeart.net employees, others appearing on the Podcast at the invitation of MyHeart.net, or other visitors to the Podcast is solely at your own risk. The Podcast and the Content are provided on an “as is” basis.

About Sheila: A 60 year old polyamorous pansexual woman. She has been on oxygen for 5 years due to rare diseases (CTEPH and Takayasu’s Arteritis) that have caused her to have very little circulation to her lungs. "I see it as just another fact of life. Being disabled hasn’t changed who I am. I still want to be seen as a vibrant, capable and sexy woman. It has been hard to feel sexy when you are attached to a hose all the time. I did a boudoir photo shoot for my sexy 60 birthday in January. I had them include my oxygen in most of the photos. It was a beautiful experience, and they made my oxygen sexy and beautiful." (Thank you Silk and Salt Photography)Full interview can be viewed on Patreon.com/AmourologyEdAmourologyEd: Sex and Alternative Lifestyle Education and Coaching Inspiring sexual and emotional wholeness through practical and compassionate training.Like and Subscribe for more information on sex, sexuality, gender, relationships, and emotional wholeness.Check out my website for more more information, to book a coaching session, or to schedule an in person workshopAges 17+ Email: Krista@amourology.net Etsy: https://www.etsy.com/shop/AmourologyEdWebsite: https://www.amourology.net/@AmourologyEd on Facebook, Twitter, InstagramFacebook Group: https://www.facebook.com/groups/AmourologyEd/Patreon: https://www.patreon.com/join/AmourologyEd?Podcasts: http://podcast.amourology.net/or wherever podcasts are found (AmourologyEd: Sex and Alternative Lifestyle Education)Videos: @AmourologyEd on YouTubeSupport the show (http://www.patreon.com/join/AmourologyEd?)

Steven Cassady, Pulmonary and Critical Care Fellow, University of Maryland, School of Medicine presents pulmonary grand rounds titled "CTEPH: Underestimated, Complex, Treatable". The objectives of the presentation are: